Why Is INCYTE CORP (INCY) Stock Up Today?

INCY stock is up 9.30% at $129.93 as of the latest trade, driven by regulatory approval and updated guidance for its key product, Opzelura. The European Commission approved Opzelura as the first steroid-free topical JAK inhibitor for moderate atopic dermatitis in adults. Incyte also raised its 2026 net sales guidance, citing strong performance across its portfolio and a settlement with the Centers for Medicare & Medicaid Services.

What Happened

The European approval of Opzelura marks a significant expansion for Incyte, providing access to a new market for this JAK inhibitor. This approval follows a recent settlement with CMS that resolved prior reimbursement issues in the U.S. and contributed to an upward revision of Opzelura’s sales guidance to $1.050B, $1.1B. Incyte also reported second-quarter 2026 net product sales of $1.49 billion, a 40% increase from the prior year, and raised its full-year net sales forecast to $5.130B, $5.260B. These developments, combined with positive analyst sentiment, fueled the sharp rise in the stock.

What The Data Shows

The stock opened at $131.56, a modest gap up from the prior close, but traded in a narrow range throughout the session. Volume remains at 0.0M shares, below the 3-month average. The stock has risen 9.0% over the last 8 sessions, reaching a new 52-week high of $132.60. Incyte’s fundamentals remain strong, with a revenue growth of 21.5% trailing twelve months and a net margin of 26.7%. Recent insider transactions show six sales totaling $5.4M over the last 90 days, with the most recent filing on July 20.

What To Watch

The company’s earnings call presentation for Q2 2026 is available, and further updates on Opzelura’s performance in the EU and U.S. will be key. Coverage breadth and analyst ratings should be monitored, especially as Oppenheimer and HC Wainwright have raised price targets to $120 and $150, respectively.